530 HIGH EFFICACY AND SAFETY OF TENOFOVIR DF IN 441 NAIVE AND NUC-EXPERIENCED CHRONIC HEPATITIS B PATIENTS: A REAL LIFE MULTICENTER PROSPECTIVE COHORT STUDY

Abstract

(W+24). Sustained virological response (SVR) defined as HBV-DNA 2000 IU/ml was observed in 24 patients 19/24 were non responders (NPV: 79%). A decline in HBsAg titer 10% at week 12 and week 24, respectively. Conclusions: In patients receiving PEG-IFN plus tenofovir, a SVR was observed in 30% and an HBsAg loss in 11%. Baseline HBsAg titer was predictive of: ≤2000 IU/ml HBsAg loss (100%) and SVR (PPV 50%); >2000 IU/ml non-response (NPV 80%). A lack of ≥10% decline in HBsAg level at week 12 or week 24 allows identifying non-responders with a high NPV 80%. An early (week 12) HBsAg level decline is associated with HBsAg loss.